Who is sponsoring NCT04167722?

NCT04167722 is sponsored by Imperial College London.

What drugs are being tested in NCT04167722?

Interventions in NCT04167722: Robotic Radical Prostatectomy.

What condition does NCT04167722 study?

NCT04167722 studies Prostate Cancer, Obesity.

Is NCT04167722 still recruiting?

NCT04167722 is currently status unknown. Last updated 22 September 2021.

Last reviewed 2021-09-22 · How we verify

NCT04167722: EXOPRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients

Status unknown Last updated 22 September 2021

What this trial tests

trial testing Robotic Radical Prostatectomy in Prostate Cancer in 100 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 October 2023

1 October 2024

Quick facts

Lead sponsor	Imperial College London
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 October 2019
Primary completion	1 October 2023
Estimated completion	1 October 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Robotic Radical Prostatectomy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Obesity — all drugs for Obesity →

Sponsor

Imperial College London

Who can join

Eligibility, male only, with Prostate Cancer or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will be collecting prostate and fat tissue from participants undergoing radical prostatectomy to culture and study in the laboratory.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical applications of stem cell-derived exosomes.
Tan F, Li X, Wang Z, Li J, et al · · 2024 · cited 390× · PMID 38212307 · DOI 10.1038/s41392-023-01704-0
Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development.
Kok VC, Yu CC. · · 2020 · cited 318× · PMID 33116515 · DOI 10.2147/ijn.s272378
Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Cancer nanotechnology: current status and perspectives.
Kemp JA, Kwon YJ. · · 2021 · cited 117× · PMID 34727233 · DOI 10.1186/s40580-021-00282-7
Clinical applications for exosomes: Are we there yet?
Perocheau D, Touramanidou L, Gurung S, Gissen P, et al · · 2021 · cited 101× · PMID 33751579 · DOI 10.1111/bph.15432
The impact of obesity on adipocyte-derived extracellular vesicles.
Kwan HY, Chen M, Xu K, Chen B. · · 2021 · cited 59× · PMID 34677643 · DOI 10.1007/s00018-021-03973-w
Pathogenetic Features and Current Management of Glioblastoma.
Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. · · 2021 · cited 42× · PMID 33670551 · DOI 10.3390/cancers13040856
Adult Stem Cell-Derived Extracellular Vesicles in Cancer Treatment: Opportunities and Challenges.
Parfejevs V, Sagini K, Buss A, Sobolevska K, et al · · 2020 · cited 32× · PMID 32397238 · DOI 10.3390/cells9051171

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04167722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 22 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04167722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing